Therapeutic efficacy and safety evaluation of weekly regimen versus intensive regimen of paclitaxel neoadjuvant chemotherapy in breast cancer

ZHAO Mingyue; ZHANG Yanhua; YANG Yang; ZHAO Rongsheng

doi:10.6039/j.issn.1001-0408.2022.24.13

您当前的位置：

首页 >

文章列表页 >

Therapeutic efficacy and safety evaluation of weekly regimen versus intensive regimen of paclitaxel neoadjuvant chemotherapy in breast cancer

更新时间：2023-02-22

- Therapeutic efficacy and safety evaluation of weekly regimen versus intensive regimen of paclitaxel neoadjuvant chemotherapy in breast cancer
- ZHONGGUO YAOFANG Vol. 33, Issue 24, Pages: 3010-3014(2022)
- 作者机构：
  
  1.北京大学第三医院药剂科，北京　100191
  2.北京大学药学院药事管理与临床药学系，北京　100191
  3.北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科/恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142
  4.北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺癌预防治疗中心/恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.24.13
  CLC： R969.3;R737.9
- Published：30 December 2022，
  
  Received：11 May 2022，
  
  Revised：17 November 2022，
扫描看全文
赵明月,张艳华,杨飏等.紫杉醇新辅助化疗单周方案对比密集方案用于乳腺癌的疗效和安全性评价 ^Δ[J].中国药房,2022,33(24):3010-3014.

.ZHAO Mingyue^1，2，3， ZHANG Yanhua³， YANG Yang⁴， ZHAO Rongsheng¹[1. Dept. of Pharmacy， Third Hospital of Peking University， Beijing 100191， China； 2. Dept. of Pharmacy Administration and Clinical Pharmacy， School of Pharmaceutical Sciences， Peking University， Beijing 100191， China； 3. Dept. of Pharmacy， Peking University Cancer Hospital＆Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education）， Beijing 100142， China； 4. Breast Cancer Prevention and Treatment Center， Peking University Cancer Hospital＆Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education）， Beijing 100142， China][J].ZHONGGUO YAOFANG,2022,33(24):3010-3014.
赵明月,张艳华,杨飏等.紫杉醇新辅助化疗单周方案对比密集方案用于乳腺癌的疗效和安全性评价 ^Δ[J].中国药房,2022,33(24):3010-3014. DOI： 10.6039/j.issn.1001-0408.2022.24.13.

.ZHAO Mingyue^1，2，3， ZHANG Yanhua³， YANG Yang⁴， ZHAO Rongsheng¹[1. Dept. of Pharmacy， Third Hospital of Peking University， Beijing 100191， China； 2. Dept. of Pharmacy Administration and Clinical Pharmacy， School of Pharmaceutical Sciences， Peking University， Beijing 100191， China； 3. Dept. of Pharmacy， Peking University Cancer Hospital＆Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education）， Beijing 100142， China； 4. Breast Cancer Prevention and Treatment Center， Peking University Cancer Hospital＆Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education）， Beijing 100142， China][J].ZHONGGUO YAOFANG,2022,33(24):3010-3014. DOI： 10.6039/j.issn.1001-0408.2022.24.13.

摘要

目的

比较紫杉醇新辅助化疗单周方案与密集方案用于乳腺癌的疗效与安全性。

方法

回顾性分析2017年1月至2020年12月北京大学肿瘤医院乳腺癌预防治疗中心收治的249例乳腺癌患者资料，采用倾向性匹配评分后，按紫杉醇不同给药频次分为单周方案组（91例）和密集方案组（91例）。单周方案组患者给予注射用盐酸表柔比星90～100 mg/m

，静脉推注，d

+注射用环磷酰胺600 mg/m

，静脉推注，d

，14 d为1周期；4个周期后序贯紫杉醇注射液80 mg/m

，静脉滴注，d

，每周1次，共12周。密集方案组患者给予注射用盐酸表柔比星（用法用量同单周方案组）+注射用环磷酰胺（用法用量同单周方案组），4个周期后序贯紫杉醇注射液175 mg /m

，静脉滴注，d

，14 d为1周期，共4个周期。化疗后24 h给予聚乙二醇化重组人粒细胞刺激因子注射液6 mg或化疗第4、6、8、10天给予人粒细胞刺激因子注射液0.3 mg。比较两组患者的临床疗效、病理完全缓解率（pCR）和不良反应发生情况。

结果

两组患者的有效率、无效率及pCR比较，差异均无统计学意义（

＞0.05）。单周方案组年龄≥50岁、已绝经、人表皮生长因子受体2阴性患者的pCR均显著高于密集方案组（

＜0.05）。密集方案组患者3级及以上中性粒细胞减少发生率显著低于单周方案组（

＜0.05），两组患者的血红蛋白减少发生率、转氨酶升高发生率、周围神经毒性发生率比较，差异均无统计学意义（

＞0.05）。

结论

在人表皮生长因子受体2阴性、年龄≥50岁及绝经后的乳腺癌患者中，紫杉醇单周化疗方案的pCR较高，但由于该方案的化疗间隔时间较短，未预防性使用升高白细胞的药物，故3级及以上中性粒细胞减少发生率较高。

Abstract

OBJECTIVE

To compare the efficacy and safety of weekly regimen versus intensive regimen of paclitaxel neoadjuvant chemotherapy for breast cancer.

METHODS

The data of 249 patients with breast cancer admitted to Breast Cancer Prevention and Treatment Center of Peking University Cancer Hospital from January 2017 to December 2020 were retrospectively analyzed. After matching with the propensity score matching method， they were divided into single-week regimen group （91 cases） and intensive regimen group （91 cases） according to the different administration frequencies of paclitaxel. The patients in single-week regimen group were given Epirubicin hydrochloride for injection 90-100 mg/m

， intravenous bolus， d

+Cyclophosphamide for injection 600 mg/m

， intravenous bolus， d

， 14 days as a cycle； after four cycles， they were given sequential injection of Paclitaxel injection 80 mg/m

， intravenous drip， d

， once a week， for 12 weeks. The patients in intensive regimen group were given Epirubicin hydrochloride for injection （same usage and dosage as single-week regimen group）+Cyclophosphamide for injection （same usage and dosage as single-week regimen group）， after 4 cycles they were given sequential injection of Paclitaxel injection 175 mg/m

， intravenous drip， d

， 14 days as a cycle， a total of 4 cycles； they were also given Polyethylene glycol recombinant human granulocyte stimulating factor injection 6 mg 24 hours after chemotherapy or 0.3 mg on the 4th， 6th， 8th and 10th day after chemotherapy. The clinical efficacy， pathologic complete remission rate （pCR） and the occurrence of adverse drug reactions were compared between two groups.

RESULTS

There were no significant difference in effective rate， ineffective rate and pCR between the two groups （

＞0.05）. The pCR of patients over 50 years old， menopause and negative for human epidermal growth factor receptor 2 in single-week regimen group was significantly higher than intensive regimen group （

＜0.05）. The incidence of neutropenia of grade 3 and above in intensive regimen group was significantly lower than single-week regimen group （

＜0.05）. There was no significant difference in the incidence of decreased hemoglobin， increased transaminase and peripheral neurotoxicity between the two groups （

＞0.05）.

CONCLUSIONS

Among the breast cancer patients with negative for human epidermal growth factor receptor 2， over 50 years old and menopause， the pCR of single-week regimen of paclitaxel is high. However， because the chemotherapy interval of this scheme is short and the drugs that increase leukocytes are not used prophylactically， the incidence of neutropenia of grade 3 and above is high.

关键词

新辅助化疗乳腺癌紫杉醇单周方案密集方案临床疗效安全性

Keywords

breast cancerpaclitaxelsingle regimenintensive regimenclinical efficacysafety

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

GRADISHAR W J，MORAN M S，ABRAHAM J，et al. NCCN guidelines® insights：breast cancer，version 4.2021[J]. J Natl Compr Canc Netw，2021，19（5）：484-493.

魏路，姚峰. 表观遗传调控在新辅助化疗中作用的研究进展[J]. 中华实用诊断与治疗杂志，2018，32（11）：1141-1144.

RASTOGI P，ANDERSON S J，BEAR H D，et al. Preo- perative chemotherapy：updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J]. J Clin Oncol，2008，26（5）：778-785.

TENG F，CORMIER T，SAUER-BUDGE A，et al. Wea- rable near-infrared optical probe for continuous monitoring during breast cancer neoadjuvant chemotherapy infusions[J]. J Biomed Opt，2017，22（1）：14001.

NELSON R. San antonio breast cancer symposium 2017[J]. Lancet Oncol，2018，19（1）：22.

SPARANO J A，ZHAO F M，MARTINO S，et al. Long-term follow-up of the E1199 phase Ⅲ trial evaluating the role of taxane and schedule in operable breast cancer[J]. J Clin Oncol，2015，33（21）：2353-2360.

中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南：2021[M]. 北京：人民卫生出版社，2021，43-48.

EISENHAUER E A，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.

《乳腺癌新辅助化疗后的病理诊断专家共识》编写组. 乳腺癌新辅助化疗后的病理诊断专家共识[J]. 中华病理学杂志，2015，44（4）：232-236.

US Department of Health and Human Services，National Institutes of Health，National Cancer Institute. Common terminology criteria for adverse events（CTCAE）version 5 [EB/OL]. [2022-04-25]. https：//ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_ v5_Quick_Reference_5x7.pdfhttps://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

CITRON M L，BERRY D A，CIRRINCIONE C，et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer：first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741[J]. J Clin Oncol，2003，21（8）：1431-1439.

SPARANO J A，WANG M L，MARTINO S，et al. Weekly paclitaxel in the adjuvant treatment of breast cancer[J]. N Engl J Med，2008，358（16）：1663-1671.

NORTON L，SIMON R. Tumor size，sensitivity to therapy，and design of treatment schedules[J]. Cancer Treat Rep，1977，61（7）：1307-1317.

NORTON L. Evolving concepts in the systemic drug therapy of breast cancer[J]. Semin Oncol，1997，24（4 Suppl 10）：S10-3-S10-10.

李丹丹. 乳腺癌新辅助化疗中紫杉醇每周与二周方案近期疗效的初步观察[D].贵州：贵阳医学院，2012.

师金，梁迪，李道娟，等.全球女性乳腺癌流行情况研究[J].中国肿瘤，2017，26（9）：683-690.

谢梅青，陈蓉，任慕兰. 中国绝经管理与绝经激素治疗指南：2018[J].协和医学杂志，2018，9（6）：512-525.

ZHU T，LIU C L，ZHANG Y F，et al. A phase Ⅱ trial of dose-dense（biweekly）paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer[J]. Breast Cancer Res Treat，2016，156（1）：117-124.

KATSUMATA N，YASUDA M，TAKAHASHI F，et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer：a phase 3，open-label，randomised controlled trial[J]. Lancet，2009，374（9698）：1331-1338.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of 9 cases of rituximab followed by belimumab in the treatment of severe systemic lupus erythematosus

Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation

Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer： a meta-analysis

Related Author

ZHAO Yuanxia

GAO Guanmin

LU Xiaojing

CHU Yaojuan

WANG Song

SHI Xiangfen

DU Shuzhang

ZHANG Xiaojian

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Zhengzhou University

Dept. of Rheumatology and Immunology， the First Affiliated Hospital of Zhengzhou University

Dept. of General Medicine， Hengshui Municipal People’s Hospital

Dept. of Rheumatology and Immunology， Hengshui Municipal People’s Hospital

College of Clinical Medicine， Hebei Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰